This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Dermatology				
Itch	Transient receptor potential A1 (TRPA1)	<p>Studies in mice suggest that inhibiting TRPA1 could help treat itch. In mouse models of chemically-induced itch, Trpa1-deficient mice spent significantly less time scratching than wild-type controls ($p < 0.01$). Next steps include examining the role of TRPA1 in a variety of chronic itch models.</p> <p>Hydra Biosciences Inc.'s TRPA1 modulator program is partnered with Cubist Pharmaceuticals Inc. and is in preclinical development to treat pain.</p> <p>Glenmark Pharmaceuticals Ltd.'s GRC 17536 is a TRPA1 antagonist in preclinical development to treat pain and respiratory disorders.</p> <p>SciBX 4(14); doi:10.1038/scibx.2011.403 Published online April 7, 2011</p>	Patent application filed; Trpa1 mouse model available for licensing	<p>Wilson, S.R. <i>et al. Nat. Neurosci.</i>; published online April 3, 2011; doi:10.1038/nn.2789</p> <p>Contact: Diana M. Bautista, University of California, Berkeley, Calif. e-mail: dbautista@berkeley.edu</p>